Primary Amyloidosis clinical trials
19 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
- Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
- Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
- Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- Teclistamab-Daratumumab in AL Amyloidosis
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
- A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
- Molecular Imaging of Primary Amyloid Cardiomyopathy
- Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
- Global Cardio Oncology Registry
- The Indiana Myeloma Registry
- Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
- Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
- A Study of AT-02 in Subjects With Systemic Amyloidosis.
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
- Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Primary Amyloidosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.